<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00774163</url>
  </required_header>
  <id_info>
    <org_study_id>FDA IND# 13710</org_study_id>
    <secondary_id>1R01AT002733-01A1</secondary_id>
    <nct_id>NCT00774163</nct_id>
  </id_info>
  <brief_title>Safety of Lactobacillus Reuteri in Healthy Volunteers</brief_title>
  <official_title>Phase 1: Safety of Lactobacillus Reuteri in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tulane University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins Bloomberg School of Public Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asociación Benéfica Prisma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tulane University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase one study to assess the safety of daily dosing of Lactobacillus reuteri in
      healthy adults in Peru. It is conducted as a preliminary study in support of a clinical trial
      to assess safety and efficacy of Lactobacillus reuteri versus placebo for treatment of
      pediatric diarrhea in Peru.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I blinded randomized study of the safety and tolerability of Lactobacillus
      reuteri DSM 17938 given daily for a period of five consecutive days. Upon enrollment subjects
      will be randomized to one of two treatment groups in a ratio of treatment to placebo of 2:1.
      Subjects will be randomized to receive either:

      A. Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose,
      given once daily for a five-day treatment period that corresponds to a dose of the closely
      related L. reuteri ATCC 55730 strain that has shown to be therapeutic for infantile colic.
      The strain used in this study (DSM 17938) has been cured of an antibiotic resistance plasmid
      found in the original BioGaia strain (L. reuteri ATCC 55730).

      B. Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing
      the Lr suspension, given once daily for a five-day study period (BioGaia AB, Stockholm,
      Sweden).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Positive Blood Culture for L. Reuteri</measure>
    <time_frame>participants were followed for an average of 36 days</time_frame>
    <description>To assess association between administration of Lactobacillus reuteri (Lr) strain DSM 17938 and abnormal lab values (CBC, BUN, Creatinine, AST, ALT, blood culture).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Daily Temperature</measure>
    <time_frame>5 days of study product administration</time_frame>
    <description>Measured daily during 5 days of study product administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Leukocyte Count on Day 5</measure>
    <time_frame>Measured on day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Alanine Aminotransferase (ALT) in Female Participants</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum ALT in Males</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Aspartate Aminotransferase (AST) in Females</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum AST in Males</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Urea Nitrogen</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Creatinine</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With at Least One PCR Positive Stool Specimen</measure>
    <time_frame>Average of 36 day follow up period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Vomiting Reported</measure>
    <time_frame>Day 0 through 6 weeks after Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Pruritis Reported</measure>
    <time_frame>Day 0 through 6 weeks after Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Headache Reported</measure>
    <time_frame>Day 0 through 6 weeks after Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Malaise Reported</measure>
    <time_frame>Day 0 through 6 weeks after Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Diarrhea Reported</measure>
    <time_frame>Day 0 through 6 weeks after Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Myalgia Reported</measure>
    <time_frame>Day 0 through 6 weeks after Day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Subjective Fever Reported</measure>
    <time_frame>Day 0 through 6 weeks after Day 0</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Lactobacillus reuteri</intervention_name>
    <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
    <arm_group_label>1</arm_group_label>
    <other_name>BioGaia Probiotic Drops</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults 18-65 with no exclusion criteria

          -  Subject is a male or, if the subject is female and of childbearing potential then she
             must have a negative serum or urine pregnancy test result within 48 hours of
             initiating study preparations and agree to use an acceptable method of contraception.
             Acceptable methods of contraception include depot forms of progesterone containing
             therapies or an intrauterine device (IUD).

        Exclusion Criteria:

          -  No enrollment of family members in households where any of the following are present:

               -  Another study participant in the household

               -  Pregnancy or current breastfeeding by any household member

               -  Presence of an infant under age 6 months living in the household

               -  Presence of immune suppressed individuals or use of immunosuppressive agents
                  (corticosteroids, methotrexate) by any household member

               -  Presence of a serious congenital anomaly or chronic medical condition that would
                  contraindicate participation in any household member, including history of
                  gastrointestinal surgery, chronic gastrointestinal illness, abnormal intestinal
                  anatomy, or abnormal bowel functionality

          -  Allergy to penicillin or cephalosporins

          -  History of antibiotic use in the last 30 days

          -  Use of probiotic products within the past 90 days

          -  History of diarrheal illness within the past 30 days

          -  Presence of fever or a pre-existing adverse event monitored in the study

          -  Positive results on serum diagnostic tests for antibodies to HIV, Hepatitis B core
             antigen, and Hepatitis C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard A Oberhelman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tulane School of Public Health and Tropical Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Margaret N Kosek, MD</last_name>
    <role>Study Director</role>
    <affiliation>Johns Hopkins Bloomberg School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Community of Santa Clara</name>
      <address>
        <city>Iquitos</city>
        <state>Loreto</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Peru</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2008</study_first_submitted>
  <study_first_submitted_qc>October 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2008</study_first_posted>
  <results_first_submitted>June 13, 2012</results_first_submitted>
  <results_first_submitted_qc>June 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 12, 2013</results_first_posted>
  <last_update_submitted>December 15, 2016</last_update_submitted>
  <last_update_submitted_qc>December 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tulane University School of Medicine</investigator_affiliation>
    <investigator_full_name>Richard A. Oberhelman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>probiotics</keyword>
  <keyword>lactobacillus</keyword>
  <keyword>reuteri</keyword>
  <keyword>none (safety only)</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Potential subjects were inoformed of the study in community meetings in Santa Clara, Peru. Interested individuals were enrolled at the study clinic between Feb. 23, 2010 and April 2, 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lactobacillus Group</title>
          <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lactobacillus Group</title>
          <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="45"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.1" spread="2.0"/>
                    <measurement group_id="B2" value="32.3" spread="2.3"/>
                    <measurement group_id="B3" value="36.8" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Peru</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Positive Blood Culture for L. Reuteri</title>
        <description>To assess association between administration of Lactobacillus reuteri (Lr) strain DSM 17938 and abnormal lab values (CBC, BUN, Creatinine, AST, ALT, blood culture).</description>
        <time_frame>participants were followed for an average of 36 days</time_frame>
        <population>2:1 randomization Lactbacillus:placebo using a randomizatin table as specified in the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Positive Blood Culture for L. Reuteri</title>
          <description>To assess association between administration of Lactobacillus reuteri (Lr) strain DSM 17938 and abnormal lab values (CBC, BUN, Creatinine, AST, ALT, blood culture).</description>
          <population>2:1 randomization Lactbacillus:placebo using a randomizatin table as specified in the protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With at Least One PCR Positive Stool Specimen</title>
        <time_frame>Average of 36 day follow up period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One PCR Positive Stool Specimen</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Vomiting Reported</title>
        <time_frame>Day 0 through 6 weeks after Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Vomiting Reported</title>
          <units>days with symptom reported</units>
          <param>Number</param>
          <units_analyzed>Days of observation</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Days of observation</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1230"/>
                <count group_id="O2" value="615"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Daily Temperature</title>
        <description>Measured daily during 5 days of study product administration</description>
        <time_frame>5 days of study product administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daily Temperature</title>
          <description>Measured daily during 5 days of study product administration</description>
          <units>Degrees Celcius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.02" spread="0.5"/>
                    <measurement group_id="O2" value="36.04" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Leukocyte Count on Day 5</title>
        <time_frame>Measured on day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Leukocyte Count on Day 5</title>
          <units>cells per cubic millimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6936" spread="1331"/>
                    <measurement group_id="O2" value="7893" spread="1168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Alanine Aminotransferase (ALT) in Female Participants</title>
        <time_frame>Day 5</time_frame>
        <population>limited to females</population>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Alanine Aminotransferase (ALT) in Female Participants</title>
          <population>limited to females</population>
          <units>units per liter (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3" spread="18.0"/>
                    <measurement group_id="O2" value="22.2" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum ALT in Males</title>
        <time_frame>Day 5</time_frame>
        <population>limited to males</population>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Serum ALT in Males</title>
          <population>limited to males</population>
          <units>units per liter (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.1" spread="29.7"/>
                    <measurement group_id="O2" value="27.8" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Aspartate Aminotransferase (AST) in Females</title>
        <time_frame>Day 5</time_frame>
        <population>limited to females</population>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Aspartate Aminotransferase (AST) in Females</title>
          <population>limited to females</population>
          <units>units per liter (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" spread="13"/>
                    <measurement group_id="O2" value="22.4" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum AST in Males</title>
        <time_frame>Day 5</time_frame>
        <population>limited to males</population>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Serum AST in Males</title>
          <population>limited to males</population>
          <units>units per liter (U/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31" spread="16.1"/>
                    <measurement group_id="O2" value="31" spread="16.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Urea Nitrogen</title>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Urea Nitrogen</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4" spread="7.0"/>
                    <measurement group_id="O2" value="19.3" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Creatinine</title>
        <time_frame>Day 5</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" spread="0.16"/>
                    <measurement group_id="O2" value="0.73" spread="0.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Pruritis Reported</title>
        <time_frame>Day 0 through 6 weeks after Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Pruritis Reported</title>
          <units>days with symptom reported</units>
          <param>Number</param>
          <units_analyzed>days of observation</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>days of observation</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1230"/>
                <count group_id="O2" value="615"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Headache Reported</title>
        <time_frame>Day 0 through 6 weeks after Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Headache Reported</title>
          <units>days with symptom reported</units>
          <param>Number</param>
          <units_analyzed>days of observation</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>days of observation</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1230"/>
                <count group_id="O2" value="615"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Malaise Reported</title>
        <time_frame>Day 0 through 6 weeks after Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Malaise Reported</title>
          <units>days with symptom reported</units>
          <param>Number</param>
          <units_analyzed>days of observation</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>days of observation</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1230"/>
                <count group_id="O2" value="615"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Diarrhea Reported</title>
        <time_frame>Day 0 through 6 weeks after Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Diarrhea Reported</title>
          <units>days with symptom reported</units>
          <param>Number</param>
          <units_analyzed>days of observation</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>days of observation</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1230"/>
                <count group_id="O2" value="615"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Myalgia Reported</title>
        <time_frame>Day 0 through 6 weeks after Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Myalgia Reported</title>
          <units>days with symptom reported</units>
          <param>Number</param>
          <units_analyzed>days of observation</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>days of observation</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1230"/>
                <count group_id="O2" value="615"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Subjective Fever Reported</title>
        <time_frame>Day 0 through 6 weeks after Day 0</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lactobacillus Reuteri Group</title>
            <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Tolerance of Lactobacillus Reuteri (Lr) Strain DSM 17938 Based on Number of Days With Subjective Fever Reported</title>
          <units>days with symptom reported</units>
          <param>Number</param>
          <units_analyzed>days of observation</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>days of observation</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1230"/>
                <count group_id="O2" value="615"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months from initiation of study</time_frame>
      <desc>AEs are scored as grade 1= mild, grade 1= moderate, grade 3 = severe, and grade 4 = life threatening based on the subject’s interpretation of their symptom severity.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lactobacillus Reuteri Group</title>
          <description>Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Placebo oil preparation, administered as 5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>Per protocol</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea and vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>laceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Lumbar pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="15" subjects_at_risk="30"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="38" subjects_affected="20" subjects_at_risk="30"/>
                <counts group_id="E2" events="23" subjects_affected="9" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>dysuria</sub_title>
                <counts group_id="E1" events="17" subjects_affected="6" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>vaginal discharge</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="30"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="7" subjects_affected="3" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Richard Oberhelman</name_or_title>
      <organization>Tulane University School of Public Health and Tropical Medicine</organization>
      <phone>504-988-2511</phone>
      <email>oberhel@tulane.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

